Comparative study of metabolic profile of women presenting with polycystic ovary syndrome in relation to body mass index


  • Akshaya S. Department of Obstetrics and Gynaecology, Kasturba Hospital, Delhi, India
  • Ratnaboli Bhattacharya Department of Obstetrics and Gynaecology, Kasturba Hospital, Delhi, India



Background: Polycystic ovary syndrome (PCOS) is characterized by hyperandrogenism, ovulatory dysfunction and polycystic ovaries (PCO). The objective was to study and compare the metabolic effects of PCOS in lean PCOS     (BMI <23) and obese PCOS (BMI >23).

Methods: Fifty healthy women who were euthyroid with age range 15-38 years who presented to gynecology OPD and diagnosed to have PCOS according to ESHRE/ASRM criteria were included in the study. BMI (body mass index) was calculated by the formula weight in kg/height in meter square. BMI were calculated were divided into 2 groups.

Lean PCOS found in patients with BMI <23 kg/m2 and overweight/obese PCOS found in patients with                      BMI >23 kg/m2.

Results: Hypertension, deranged lipid profile, insulin resistances were frequently seen in obese PCOS than in lean PCOS. Deranged GTT (glucose tolerance test) was not statistically significant in these two groups p=0.15.

Conclusions: The study concludes that obese PCOS were at higher risk of developing hypertension, deranged lipid profile and insulin resistance than lean PCOS as obesity is significant contributor to metabolic syndrome. Glucose intolerance was present in both obese and lean PCOS.


Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. 2004 Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19-25.

Ford ES, Giles WH, Dietz. WHO prevalence of metabolic syndrome among US adults: findings from the third national health and nutrition examination survey. J Am Med Asso. 2002;287:356-9.

Gambineri A, Pelusi C,Vicennati V, Pasquali R. obesity and polycystic ovary syndrome. Int J obes relat metab disodr 2002; 26:883-96

Dunaif A, Segal KR, Futterweit W. Profound peripheral insulin resistance, independent of obesity, in PCOS. 1989;38:1165-74.

Paradisi R, Venturoli S, Pasquali R. Effect of obesity on gonadotrophin secretion in patients with polycystic ovary disease. J Endocrinol Invest. 1986;9:139-44.

Wild RA. Long term health consequences of PCOS. Hum Reprod Update. 2002;8(3):231-41.

Saxena P, Prakash A, Nigam A, Mishra A. PCOS: is obesity a sine qua non? a clinical, hormonal and metabolic assessment in relation to BMI. Indian J Endocrinol Metab. 2012;16(6):996-9.

Mckeigue PM, Shah B, Marmot MG. Relation of central obesity and insulin resistance with high diabetes prevalence and cardiovascular risk in south Asians. Lancet. 1991;337:382-6.

Morales AJ, Laughlin GA, Butzow T, Maheshwari H. Insulin, somatotropic and leutinizing hormone axes in lean and obese with PCOS: common and distinct features. J Clinical Endocrino Metab. 1996;81:8.

Toprak S, Yonem A, Cakir B. Insulin resistance in nonobese patients with polycystic ovary syndrome. Hormone Research. 2001;55(2):65-70.

Boudreaux MY, Talbott EO, Kip KE, Brooks MM, Witchel SF. Risk of T2DM and impaired fasting glucose among PCOS subjects; results of an 8 year follow up. Curr Diab Rep. 2006;6:77-83.

Joshi B, Mukherjee S, Patil A, Purandare A. A cross-sectional study of polycystic ovarian syndrome among adolescent and young girls in Mumbai, India. Indian J Endocr Metab. 2014;18:317-24.

Holte J, Bergh T, Berne C, Berglund L, Lithell H. Enhanced early insulin response to glucose in relation to insulin resistance in women with polycystic ovary syndrome and normal glucose tolerance. J Clin Endocrinol Metab. 1994;78:1052-8.






Original Research Articles